Which of the following counselling points is best to discuss with a patient who is taking levothyroxine?
A. It can be taken with calcium supplements or dietary foods with no problems
B. Take it in the morning on an empty stomach, at least 30 mins (before breakfast)
C. If you miss a dose, make sure to double the next scheduled levothyroxine dose
D. Take it immediately after the breakfast with a large glass of water to avoid stomach upset
B. Take it in the morning on an empty stomach, at least 30 mins (before breakfast)
Levothyroxine absorption is reduced by food, calcium, iron, and certain other medications or supplements. Standard counselling is therefore to take it once daily in the morning on an empty stomach, ideally 30–60 minutes before breakfast (and separated by several hours from interacting products such as calcium).
A is incorrect: calcium supplements and many foods/interfere with absorption and should be separated.
C is incorrect: missed doses should not be doubled; take the next dose as scheduled (or seek advice if several doses are missed).
D is incorrect: taking it after breakfast reduces absorption; the empty-stomach timing is preferred.
Key counselling points:
- Take levothyroxine in the morning with a full glass of water.
- Take it on an empty stomach, 30–60 minutes before breakfast.
- Separate calcium and iron supplements by at least 4 hours, as they can reduce levothyroxine absorption.
- Take it consistently at the same time every day.
- Do not double the next dose automatically if a dose is missed; follow the prescriber's instructions.
Which of the following is the best treatment for a 75 year-old woman with urinary incontinence?
A. Imipramine
B. Oxybutynin
C. Duloxetine
D. Doxazosin
B. Oxybutynin
Urinary incontinence in older women is commonly urge (overactive bladder/detrusor overactivity) or mixed. Among the listed options, oxybutynin (an antimuscarinic/antispasmodic) is the most appropriate pharmacologic choice for urge incontinence because it reduces involuntary detrusor contractions and improves urgency, frequency, and urge leakage.
A (Imipramine): A tricyclic antidepressant sometimes used off-label for mixed or nocturnal incontinence, but it has strong anticholinergic and cardiac effects (orthostasis, QT prolongation) and is generally avoided in the elderly.
C (Duloxetine): An SNRI with evidence for stress urinary incontinence (increases urethral sphincter tone) in some guidelines/regions, but it is not first-line, is not indicated for pure urge incontinence, and carries risks (nausea, hyponatremia, falls) in older adults.
D (Doxazosin): An alpha-1 blocker used for overflow symptoms or BPH in men; in women it can reduce urethral resistance (worsening stress incontinence) and cause orthostatic hypotension/falls, making it unsuitable.
Important caveats for a 75-year-old: Immediate-release oxybutynin has a high anticholinergic burden and is listed in Beers criteria as potentially inappropriate in older adults (risk of confusion, dry mouth, constipation, falls). Prefer extended-release, transdermal, or alternative agents (e.g., other antimuscarinics with lower CNS penetration or a β3-agonist such as mirabegron) when possible, start low, and combine with behavioral measures (pelvic floor training, bladder training). Always confirm the incontinence type, rule out reversible causes, and weigh risks/benefits.
For stress urinary incontinence (SUI) in a 75-year-old woman, the best choice among the given options is C. Duloxetine.
Why duloxetine?
Duloxetine (an SNRI) increases urethral sphincter tone by enhancing serotonin and norepinephrine activity in the sacral spinal cord. It has evidence of efficacy for moderate-to-severe SUI (or stress-predominant mixed incontinence) in women, including older adults.
It is approved for this indication in some regions (e.g., Europe) and may be considered when a woman prefers to avoid or is unsuitable for surgery.
Typical dosing starts lower (e.g., 20 mg twice daily) and titrates to 40 mg twice daily to improve tolerability. Reassess after 2–4 weeks.
Why the others are not suitable for pure SUI
Oxybutynin: Targets detrusor overactivity (urge incontinence). It has little to no benefit for pure stress leakage and adds unnecessary anticholinergic burden in the elderly.
Imipramine: Has some historical off-label use (alpha-agonist + anticholinergic effects that may increase outlet resistance), but evidence is weak/poor quality. Side-effect risks (cardiac, orthostasis, strong anticholinergic effects) make it generally inappropriate in older adults.
Doxazosin: An alpha-1 blocker that relaxes the bladder neck/urethra. This can worsen stress incontinence and also causes orthostatic hypotension and falls risk — avoid in women with SUI.
Important practical points for a 75-year-old
First-line treatment is always non-drug: Supervised pelvic floor muscle training (Kegels), weight loss if overweight, management of constipation/chronic cough, fluid/caffeine modification, and consideration of a continence pessary.
Duloxetine is a second-line pharmacologic option only after conservative measures and shared decision-making. Counsel about common side effects (nausea, dry mouth, fatigue, constipation) and the need for gradual titration/discontinuation. Caution is needed with hepatic impairment, uncontrolled hypertension, or increased hyponatremia risk.
If symptoms are mixed (stress + urge), treat the predominant component first; combination approaches may be needed.
Refer for specialist assessment (urodynamics or surgical options such as mid-urethral sling) if conservative and pharmacologic measures fail or if the patient desires definitive treatment.
In short: among the listed drugs, duloxetine is the only one with a rational mechanism and supporting evidence for stress incontinence.
A 68-year-old woman with type-2 diabetes, neuropathy and seizures has been newly diagnosed with depressive illness. Which of the following medication would be best to initiate?
A. Bupropion
B. Duloxetine
C. Paroxetine
D. Amitriptyline
B. Duloxetine
This patient has depression plus diabetic neuropathy and a seizure history. Duloxetine is the best choice among the options because it is an SNRI that treats major depressive disorder and is FDA-approved (and guideline-supported) for diabetic peripheral neuropathic pain. It can therefore address two problems with one agent.
Why the other options are less suitable
A. Bupropion — Contraindicated or strongly cautioned in patients with seizure disorders because it lowers the seizure threshold. Although it is weight-neutral (or associated with modest weight loss), which can be helpful in type 2 diabetes, the seizure risk makes it inappropriate here.
C. Paroxetine — An SSRI that can treat depression but has no specific benefit for neuropathic pain. It also has more anticholinergic effects, a higher risk of weight gain, and more discontinuation symptoms than many other SSRIs, which are undesirable in an older adult with diabetes.
D. Amitriptyline — A tricyclic antidepressant that has some utility for neuropathic pain at low doses, but it is highly anticholinergic and sedating. In a 68-year-old it increases risks of falls, confusion, orthostatic hypotension, cardiac conduction effects, and weight gain; it also can lower the seizure threshold. It is generally avoided in older adults (Beers criteria).
Additional practical notes:
Start duloxetine at a low dose (e.g., 30 mg daily) and titrate as tolerated while monitoring for nausea, blood pressure changes, and any effect on glycemic control. Continue usual diabetes and seizure management, and reassess mood and pain response after several weeks. Non-pharmacologic measures (exercise, sleep hygiene, diabetes optimization) remain important adjuncts.
Which of the following counseling points is most important to discuss with a patient who is taking carbidopa/levodopa?
A. Should be taken on an empty stomach
B. High-fat meal may increase the absorption
C. Should not be taken with calcium supplements
D. High-protein meal may decrease the absorption
D. High-protein meal may decrease the absorption
Levodopa (the active component of carbidopa/levodopa) is absorbed via the same large neutral amino-acid transporters used by dietary protein. High-protein meals can therefore compete with levodopa for absorption in the gut and transport across the blood–brain barrier, reducing its effectiveness and potentially causing delayed or incomplete “on” periods. This is a classic and clinically important counseling point for patients with Parkinson’s disease.
Why the other options are less appropriate
A: Taking the medication on an empty stomach (or at least 30–60 minutes before a meal) can improve absorption and is often recommended, especially if nausea is not an issue. However, the more specific and critical interaction highlighted in counseling is the protein effect.
B: High-fat meals do not meaningfully increase absorption of carbidopa/levodopa; they may slow gastric emptying but are not a primary concern compared with protein.
C: Calcium supplements are not a major interaction with carbidopa/levodopa (iron-containing supplements are more relevant and should be separated by a couple of hours).
Practical counseling tips
Take doses consistently relative to meals.
If the “protein effect” is noticeable, space the medication 30–60 minutes before or 1–2 hours after high-protein foods, or redistribute most daily protein to the evening meal.
A small low-protein snack can be used if nausea occurs on an empty stomach.
Do not eliminate protein entirely—adequate intake remains important for nutrition and muscle health.
This protein interaction is the most important point among the listed options to discuss with patients taking carbidopa/levodopa.
A new born baby is about to get discharged with his mother. Which of the following vaccines is indicated?
A. MMR vaccine
B. Influenza vaccine
C. Rotavirus vaccine
D. Hepatitis B vaccine
D. Hepatitis B vaccine
The hepatitis B vaccine is the only one among the listed options routinely indicated for a newborn around the time of hospital discharge. Standard practice (and long-standing recommendations) is to give the first dose of hepatitis B vaccine shortly after birth—ideally within 24 hours (or within 12 hours if the mother is HBsAg-positive or status is unknown)—before the baby goes home. This provides early protection against perinatal and early postnatal transmission.
Why the others are not indicated at birth
A. MMR vaccine: First dose is given at 12 months of age (or later). It is a live vaccine and not appropriate for newborns.
B. Influenza vaccine: Not recommended until 6 months of age.
C. Rotavirus vaccine: Oral live vaccine series starts at approximately 6–8 weeks / 2 months of age (not at birth).
Note on recent guidance: Some advisory bodies have moved toward shared clinical decision-making for the birth dose in infants born to confirmed HBsAg-negative mothers. However, among the choices given, hepatitis B remains the vaccine indicated in the newborn/discharge setting; the others have no role at this age.
Disclaimer:
This blog post is intended for educational and examination-preparation purposes only. The clinical pharmacy MCQs, answers, and explanations are designed to support pharmacy students, PharmD graduates, pharmacists, and healthcare professionals preparing for licensing and competitive examinations, including NAPLEX, DHA, MOH, HAAD, SPLE, and Prometric exams.
The information provided is based on general clinical knowledge and established medical recommendations. It should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Clinical guidelines, drug recommendations, and vaccination schedules may vary between countries and are subject to change. Always consult current clinical guidelines, official regulatory recommendations, and qualified healthcare professionals before making clinical decisions.
Educational Resource: PharmaAssist
0 Comments